Is Sarepta Stock (SRPT) Halal? A Complete Analysis

The Short Answer

Sarepta stock (SRPT) is generally considered halal for Muslim investors, subject to the balance-sheet ratios. Sarepta Therapeutics is a commercial-stage biotechnology company developing and marketing RNA-based and gene therapies, with a leading franchise in treatments for Duchenne muscular dystrophy and a broader rare-disease pipeline. Developing and selling medicines is a permissible activity that benefits human health, so the business-activity screen passes.

As with any biotech, the verdict depends on the balance sheet — confirm the debt and receivables ratios against the latest filings, and purify the portion of returns attributable to interest income on cash and investments.

Sharia Screening Methodology

Islamic scholars use several criteria to screen stocks:

• Business activity screen: Is the company's primary business halal?
• Debt ratio: Total debt / market cap must be under 33%
• Interest income: Interest income / total revenue must be under 5%
• Haram revenue: Revenue from haram sources must be under 5%
• Receivables ratio: Total receivables / total assets must be under 49–70% (varies by board)

What Sarepta Does

Sarepta Therapeutics, Inc. (headquartered in Cambridge, Massachusetts) is a genetic-medicine company focused on rare diseases:

• RNA therapeutics: Exon-skipping treatments for Duchenne muscular dystrophy.
• Gene therapy: Gene-transfer programs for Duchenne and other rare conditions.
• Pipeline: A broad rare-disease research pipeline across multiple modalities.

Developing and selling medicines that treat serious diseases is a permissible activity, so the business-activity screen passes.

Why It Passes (and What to Check)

1. Permissible Core Business

Sarepta's revenue comes from therapies that treat rare genetic diseases — a clearly permissible activity that benefits human health. There is no haram revenue line.

2. Debt Ratio (Confirm Against Filings)

Biotech companies can carry convertible or other interest-bearing debt, so confirm the total-debt-to-market-cap ratio against the 33% threshold using the latest filings.

3. Interest Income (Purify)

Sarepta's March 31, 2026 filing reports $6.36 million of investment income interest, or 0.87% of first-quarter revenue. The corresponding purification treatment depends on the scholar or methodology followed.

Financial Ratios

Based on Sarepta's March 31, 2026 Form 10-Q (USD millions):

• Debt / Assets: 26.37% — below the examined limits ✅
• Liquidity / Assets: 20.55% — below the examined limits ✅
• Receivables + Cash / Assets: 27.03% — below the examined limits ✅
• Investment income interest / Revenue: 0.87% disclosed ⚠️

The examined asset ratios pass. Pharmaceutical activity is generally permissible, while collaboration and product-level classification remain incomplete.

What About Purification?

Sarepta discloses investment income interest, but this page does not infer a scholar-approved purification percentage. Investors should follow the methodology and scholarly guidance they use.

Methodology Interpretation

The current filing-based asset ratios pass, while collaboration revenue, product-level activity, market-cap denominators and purification remain methodology-dependent. This is a ZakatInvest analysis, not an official index or agency classification.

Bottom Line

Sarepta (SRPT) is generally halal for Muslim investors, subject to methodology. The rare-disease medicine business is generally permissible and the March 31, 2026 asset ratios pass; collaboration activity and purification remain review items. Re-screen periodically given the volatility of biotech.